Inhibitor Therapeutics, Inc. (INTI) — 10-Q Filings
All 10-Q filings from Inhibitor Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Inhibitor Therapeutics' Cash Dwindles Amid Rising R&D Costs
— Nov 13, 2025 Risk: high
Inhibitor Therapeutics, Inc. (INTI) reported a net loss of $2,004,972 for the nine months ended September 30, 2025, an increase from the $1,917,358 net loss in -
Inhibitor Therapeutics' Losses Widen Amid R&D Spend, Cash Dwindles
— Aug 13, 2025 Risk: high
Inhibitor Therapeutics, Inc. (INTI) reported a net loss of $1,292,788 for the six months ended June 30, 2025, an increase from a net loss of $1,186,401 for the -
Inhibitor Therapeutics Files Q1 2025 10-Q
— May 14, 2025 Risk: low
Inhibitor Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as HedgePath Pharmaceuticals, Inc. and COMMONWEALT -
Inhibitor Therapeutics Files Q3 2024 10-Q
— Nov 12, 2024 Risk: low
Inhibitor Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position and operations, includ -
Inhibitor Therapeutics Files Q2 2024 10-Q
— Aug 6, 2024 Risk: medium
Inhibitor Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as HedgePath Pharmaceuticals, Inc. and COMMONWEALTH -
Inhibitor Therapeutics, Inc. Files 10-Q for Q1 2024
— May 13, 2024 Risk: low
Inhibitor Therapeutics, Inc. (INTI) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Inhibitor Therapeutics, Inc. filed its 10-Q report for the qua
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX